Pluvicto 1 000 MBq/mL solution for injection/infusion clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
This study is looking at a new treatment called Lutetium-177-PSMA for men with prostate cancer that hasn't spread widely and is sensitive to hormone therapy. It aims to see if this treatment can slow down the cancer's growth.
For: prostate cancerCyprus · Netherlands - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial)
This study looks at a new combination of treatments, Ipilimumab and Pluvicto, for men with very high-risk prostate cancer before they have surgery. Researchers want to see if this combination is safe and helps shrink the cancer, making surgery easier and more effective.
Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
This study is looking at a new treatment called Pluvicto for a rare type of cancer called adenoid cystic carcinoma, which starts in the salivary glands. Doctors want to see how safe and effective this special medicine is for patients whose cancer has come back or spread.
For: Adenoid cystic carcinomaPoland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
This study compares two treatments, Lutetium-177 rhPSMA-10.1 and Pluvicto, for men with advanced prostate cancer that has spread. Researchers want to see which treatment delivers more helpful radiation to the cancer and less to healthy body parts like the kidneys.
For: PSMA-positive non-curative metastatic castration-resistant prostate cancerSpain · Germany · France - AuthorisedTherapeutic confirmatory (Phase III)
Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
This study, called STAMPEDE2, is looking at new treatments for men with prostate cancer that has spread. It compares different treatments, including a drug called Pluvicto, to see if they help men live longer and have a better quality of life.
For: Metastatic hormone sensitive prostate cancerIreland · Germany · Spain